AGE-HSA

AcronymDefinition
AGE-HSAAdvanced Glycation End Product-modified Human Serum Albumin
References in periodicals archive ?
Human umbilical vein endothelial cells (HUVECs) were divided into four groups based on treatment, as follows: 200 [micro]g/ml of HSA and 100 mg/dl of glucose (normal group); 200 [micro]g/ml of AGE-HSA and 250 mg/dl of glucose (diabetic group); 200 [micro]g/ml of AGE-HSA and 250 mg/dl of glucose with vitamin D (50 ng/ml) (VD treatment group); and 200 [micro]g/ml of AGE-HSA, 250 mg/dl of glucose, vitamin D (50 ng/ml), and VDR siRNA (VD antagonist group).
Normal group (200 [micro]g/ml human serum albumin (HAS) and 100 mg/dl glucose); diabetic group (200 [micro]g/ml AGE-HSA and 250 mg/dl glucose); vitamin D treatment group (vitamin D 50 nm, 200 [micro]g/ml AGE-HSA, and 250 mg/dl glucose); and vitamin D antagonist group (vitamin D 50 nm, VDR siRNA 10 nm, 200 [micro]g/ml AGE-HSA, and 250 mg/dl glucose).